We conducted a randomized controlled trial in @ subjects with early T@D who received the GLP-@ analog exenatide ( n = @ ) , the dipeptidyl peptidase IV inhibitor sitagliptin ( n = @ ) , or the sulfonylurea glimepiride ( n = @ ) as an active comparator insulin secretagogue for @ months .